HC Wainwright Reiterates “Buy” Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $19.00 target price on the stock.

Other analysts have also recently issued reports about the company. Ascendiant Capital Markets increased their price objective on NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a research report on Thursday, September 12th. EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 21st.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ:NRXP opened at $1.26 on Monday. The firm has a market capitalization of $15.23 million, a PE ratio of -0.59 and a beta of 1.27. NRx Pharmaceuticals has a 1 year low of $1.10 and a 1 year high of $7.33. The firm’s 50-day moving average is $1.39 and its two-hundred day moving average is $2.16.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC purchased a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned approximately 0.14% of NRx Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.